{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:19:29Z","timestamp":1783606769241,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The objective was to evaluate the safety and effectiveness of soft-tissue augmentation of calcium hydroxylapatite (Radiesse) in patients with facial lipoatrophy secondary to human immunodeficiency virus disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This 18-month, prospective, open-label, multicenter clinical trial of calcium hydroxylapatite for soft-tissue augmentation of patients with facial lipoatrophy enrolled 100 subjects (94 men and six women).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Correction of facial lipoatrophy was evaluated by comparing changes from baseline using the Global Aesthetic Improvement Scale, with confirmation using standardized photography. All 100 patients were determined to be improved or better at 3 months. Secondary effectiveness endpoints\u2014improvement at 6 months on the scale and skin thickness measurements at 3 and 6 months\u2014were also met. Twelve-month data and 18-month scale scores were also available. One hundred percent of assessable patients were rated as improved or better on the scale at every time point through 12 months; 91 percent were improved or better at 18 months. \u201cYes\u201d responses to all patient satisfaction questions ranged from 97 percent to 100 percent at every evaluation through 12 months. In addition, skin thickness measurements at 12 months remained statistically better than those at baseline. Eighteen-month patient satisfaction and skin thickness measurements were not available at the time of submission. Adverse events reported through 12 months were generally mild (ecchymosis, edema, erythema, pain, and pruritus), not unexpected, and generally short in duration. Eighteen-month safety data were not available at the time of submission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Radiesse is an appropriate and well-tolerated treatment for patients with facial lipoatrophy. It demonstrates an excellent safety profile, causes immediate augmentation of the soft tissues, and appears to provide relatively long-lasting improvement in appearance, with very high patient satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/01.prs.0000234847.36020.52","type":"journal-article","created":{"date-parts":[[2006,8,28]],"date-time":"2006-08-28T04:04:09Z","timestamp":1156737849000},"page":"34S-45S","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":97,"title":["Prospective, Open-Label, 18-Month Trial of Calcium Hydroxylapatite (Radiesse) for Facial Soft-Tissue Augmentation in Patients with Human Immunodeficiency Virus-Associated Lipoatrophy: One-Year Durability"],"prefix":"10.1097","volume":"118","author":[{"given":"Stacey L.","family":"Silvers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Eviatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Echavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20251119","first-page":"303","article-title":"Metabolic complications of HIV-1-antiretroviral therapy: The lipodystrophy syndrome.","volume":"24","author":"Borderi","year":"2001","journal-title":"New Microbiol"},{"key":"R2-8-20251119","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"R3-8-20251119","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4158\/EP.7.6.430","article-title":"Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection.","volume":"7","author":"Graber","year":"2001","journal-title":"Endocr. Pract"},{"key":"R4-8-20251119","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/135965350400900412","article-title":"Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients.","volume":"9","author":"Jan","year":"2004","journal-title":"Antivir. Ther"},{"key":"R5-8-20251119","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mito.2004.05.008","article-title":"Role of mitochondria in HIV lipoatrophy: Insight into pathogenesis and potential therapies.","volume":"4","author":"McComsey","year":"2004","journal-title":"Mitochondrion"},{"key":"R6-8-20251119","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dki165","article-title":"Current perspectives on HIV-associated lipodystrophy syndrome.","volume":"56","author":"Milinkovic","year":"2005","journal-title":"J. Antimicrob. Chemother"},{"key":"R7-8-20251119","first-page":"639","article-title":"Management options for facial lipoatrophy.","volume":"14","author":"Cofrancesco","year":"2004","journal-title":"AIDS Read"},{"key":"R8-8-20251119","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study.","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch. Intern. Med"},{"key":"R9-8-20251119","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: Risks and impact on clinical decision making.","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"R10-8-20251119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"R11-8-20251119","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00126334-200309010-00008","article-title":"Gender differences in antiviral drug-related adipose tissue alterations: Women are at higher risk than men and develop particular lipodystrophy patterns.","volume":"34","author":"Galli","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"R12-8-20251119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00002018-200124030-00001","article-title":"Lipodystrophy syndrome in patients with HIV infection: Quality of life issues.","volume":"24","author":"Martinez","year":"2001","journal-title":"Drug Saf"},{"key":"R13-8-20251119","first-page":"369","article-title":"Relationship between lipoatrophy and quality of life.","volume":"15","author":"Echavez","year":"2005","journal-title":"AIDS Read"},{"key":"R14-8-20251119","first-page":"24","article-title":"Restorative treatment approaches for HIV-associated lipoatrophy.","volume":"10","author":"Roth","year":"2005","journal-title":"PRN Notebook"},{"key":"R15-8-20251119","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00042728-200501000-00019","article-title":"Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy.","volume":"31","author":"Gooderham","year":"2005","journal-title":"Dermatol. Surg"},{"key":"R16-8-20251119","first-page":"3","article-title":"The aging face and nonsurgical total facial restoration.","volume":"19","author":"Werschler","year":"2006","journal-title":"Cosmet. Dermatol"},{"key":"R17-8-20251119","first-page":"9","article-title":"Aesthetic considerations in the treatment of facial lipoatrophy.","volume":"19","author":"Ditre","year":"2006","journal-title":"Cosmet. Dermatol"},{"key":"R18-8-20251119","first-page":"823","article-title":"Radiesse for facial rejuvenation.","volume":"18","author":"Felderman","year":"2005","journal-title":"Cosmet. Dermatol"},{"key":"R19-8-20251119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.sder.2004.09.005","article-title":"Biocompatibility of microparticles into soft tissue fillers.","volume":"23","author":"Laeschke","year":"2004","journal-title":"Semin. Cutan. Med. Surg"},{"key":"R20-8-20251119","first-page":"10","article-title":"Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse).","author":"Comite","year":"2004","journal-title":"Dermatol. Online J"},{"key":"R21-8-20251119","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/archfaci.6.4.234","article-title":"Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation.","volume":"6","author":"Tzikas","year":"2004","journal-title":"Arch. Facial Plast. Surg"},{"key":"R22-8-20251119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/147641704100003048","article-title":"Clinical, histologic and electron microscope findings after injection of a calcium hydroxylapatite filler.","volume":"6","author":"Marmur","year":"2004","journal-title":"J. Cosmet. Laser Ther"},{"key":"R23-8-20251119","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2004-861759","article-title":"Radiance.","volume":"20","author":"Flaharty","year":"2004","journal-title":"Facial Plast. Surg"},{"key":"R24-8-20251119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.sap.0000168292.69753.73","article-title":"Reliable soft tissue augmentation: A clinical comparison of injectable soft-tissue fillers for facial-volume augmentation.","volume":"55","author":"Kanchwala","year":"2005","journal-title":"Ann. Plast. Surg"},{"key":"R25-8-20251119","first-page":"588","article-title":"A randomized, double blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the corrections of nasolabial folds.","volume":"29","author":"Narins","year":"2003","journal-title":"Dermatol. Surg"},{"key":"R26-8-20251119","first-page":"979","article-title":"HIV-associated facial lipoatrophy.","volume":"28","author":"James","year":"2002","journal-title":"Dermatol. Surg"},{"key":"R27-8-20251119","first-page":"456","article-title":"Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines.","volume":"29","author":"Sommer","year":"2003","journal-title":"Dermatol. Surg"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006534-200609011-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T20:01:39Z","timestamp":1763582499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006534-200609011-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":27,"journal-issue":{"issue":"3S","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.prs.0000234847.36020.52","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}